DrugPatentWatch Database Preview
Cumberland Pharms Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for CUMBERLAND PHARMS, and what generic alternatives to CUMBERLAND PHARMS drugs are available?
CUMBERLAND PHARMS has seven approved drugs.
There are twenty-six US patents protecting CUMBERLAND PHARMS drugs.
There are one hundred and eighty-one patent family members on CUMBERLAND PHARMS drugs in thirty-eight countries and fifteen supplementary protection certificates in fourteen countries.
Summary for Cumberland Pharms
| International Patents: | 181 |
| US Patents: | 26 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 7 |
Drugs and US Patents for Cumberland Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | 6,872,701 | Start Trial | Y | Start Trial | |||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | RX | Yes | Yes | 9,114,068 | Start Trial | Start Trial | ||||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | RX | Yes | Yes | 9,138,404 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cumberland Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cumberland Pharms | VAPRISOL | conivaptan hydrochloride | INJECTABLE;INTRAVENOUS | 021697-001 | Dec 29, 2005 | 5,723,606 | Start Trial |
| Cumberland Pharms | VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER | conivaptan hydrochloride | INJECTABLE;INTRAVENOUS | 021697-002 | Oct 8, 2008 | 5,723,606 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUMBERLAND PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
International Patents for Cumberland Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20120089444 | Start Trial |
| Japan | 2007534630 | Start Trial |
| South Korea | 101971412 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cumberland Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1292612 | 36/2011 | Austria | Start Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | 122011100062 | Germany | Start Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | PA2012002 | Lithuania | Start Trial | PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
